Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender
• People with a laboratory-confirmed diagnosis of CD20-positive follicular lymphoma (a type of slow-growing blood cancer), classified as Grade 1, 2, or 3A under standard medical guidelines
• People with advanced-stage disease (Stage III or IV), or Stage II with a large tumour mass, who also meet at least one of the following: a tumour or lymph node measuring 7 cm or more; symptoms or organ problems caused by growing lymph nodes or tumours; fever, night sweats, or unintentional weight loss of more than 10% of body weight within 6 months; fluid build-up in the chest or abdomen from the lymphoma; low blood counts caused by lymphoma in the bone marrow; three or more lymph nodes each measuring at least 3 cm; or an enlarged spleen causing symptoms
• People who have never received systemic (whole-body) treatment for this type of lymphoma before
• People with a general health and activity level rated at 2 or below on a standard medical scale (meaning able to carry out basic self-care, though possibly not all physical activity)
• People with at least one tumour that is measurable on a scan (larger than 2 cm)
• People with a life expectancy of at least 6 months
• People whose blood counts, liver, and kidney function meet minimum levels required by the trial (confirm with trial site for specific values)
• People who are willing and able to use highly effective contraception during the trial and for 4 weeks after treatment ends (applies to people who could father or become pregnant)
• People who are willing to sign a consent form and take part voluntarily
• People who can provide tumour tissue samples (either previously stored or freshly collected) for laboratory testing

Who may not be able to join:

• People whose lymphoma has spread to the brain or spinal fluid, or whose cancer has changed into a more aggressive type (such as diffuse large B-cell lymphoma)
• People with Grade 3B follicular lymphoma or transformed follicular lymphoma
• People with Stage I follicular lymphoma
• People with a history of another cancer, unless they have been free of that cancer for at least 5 years and their treating doctor considers the risk of it returning to be low (some exceptions may apply for certain skin cancers, early prostate cancer, or specific cervical conditions — confirm with trial site)
• People who have taken an experimental drug, certain antibiotics, or who have participated in another interventional clinical trial within the 4 weeks before enrolling
• People who have had major surgery (other than a lymph node biopsy) within 14 days before enrolling, or who are expected to need major surgery during the trial
• People who have previously been treated with zanubrutinib, obinutuzumab, or lenalidomide
• People with immune system disorders, certain autoimmune diseases, or those who have been taking high-dose steroid or immune-suppressing medications within 7 days before enrolling
• People with severe liver disease, severe malnutrition, or failure of multiple organs including the kidneys
• People with significant heart problems, including severe heart failure, a heart attack within the past 6 months, dangerous heart rhythm problems, uncontrolled high blood pressure, or unstable chest pain
• People with active HIV infection, active hepatitis B or C infection at significant levels, or other uncontrolled serious infections
• People with bleeding disorders, clotting abnormalities, or a blood clot event within the past 3 months
• People with a known severe allergy to any of the ingredients in the study medications
• People who are pregnant, breastfeeding, or unwilling to use effective contraception
• People whom the trial doctors consider unsuitable for other medical reasons

Important: Always verify eligibility with the trial site directly before applying.